Posted inLondon Stock Exchange
GSK enters agreement to acquire Nuvalent, Inc. for $10.6 billion
· Multi-product oncology deal for assets that have validated targets and aim to address efficacy and/or tolerability limitations of existing therapies · Includes two late-stage, potential best-in-class ROS1 (zidesamtinib) and ALK (neladalkib) inhibitors…










